Find policies, billing codes, payers, states, and providers
Salivary Hormone Testing
Customize your policy alerts
Sign up for all Oscar Health policy alerts
Know when Oscar Health releases new policies or updates existing guidance.
Monitor payer policy activity
Defines Oscar Health's coverage stance and clinical guidance for salivary steroid hormone testing (e.g., cortisol, estrogens, progesterone, androgens) including indications, limitations, and scientific background for providers submitting claims.
No material clinical or coverage changes in this revision.
Coverage Criteria for Salivary Hormone Testing
inv-01: Initial testing for suspected Cushing syndrome
Covered when ALL of the following are met for the specified indication:
LNSC is a first-line diagnostic test and should be obtained at least twice; diagnosis of Cushing syndrome is established when at least two different first-line tests are abnormal (e.g., LNSC and 24-hour urinary free cortisol).
inv-02: Not medically necessary uses
Not covered for the following clinical purposes due to lack of sufficient evidence:
Salivary hormone testing does not meet criteria for these indications.
inv-03: Use of salivary hormone testing for individualized hormone therapy or monitoring
Not supported by major professional societies when used to individualize hormone therapy or determine dosing:
See society guidance for details.
These limitations undermine clinical utility for individualized dosing.
Regulatory status affects validation and interpretation of results.
inv-04: Diagnostic use for Cushing's syndrome/adrenal disorders
Recommended use-case in certain diagnostic contexts:
Follow guideline-recommended diagnostic steps and obtain multiple LNSC measurements as part of initial biochemical testing.
Salivary steroid hormone testing is limited in scope under this policy. It meets criteria only for late‑night salivary cortisol (LNSC) testing in individuals with signs or symptoms of Cushing syndrome (see diagnostic criteria), and is otherwise considered not to meet criteria for many common clinical applications. Specifically, salivary hormone testing does not meet criteria for the screening, diagnosis, or monitoring of menopause, infertility, endometriosis, polycystic ovary syndrome (PCOS), premenstrual syndrome, osteoporosis, sexual dysfunction, seasonal affective disorder, depression, multiple sclerosis, sleep disorders, or conditions related to aging due to insufficient published evidence of clinical benefit.
Professional society guidance and agency statements indicate that salivary hormone testing should not be used to determine dosing for compounded menopausal hormone therapy or to tailor individualized hormone therapy. Statements from ACOG/ASRM and NAMS conclude that salivary assays lack accuracy and precision for this purpose, that salivary levels are unreliable due to large intra‑patient variability and pharmacokinetic differences, and that saliva‑based dosing decisions are not supported by current evidence.
Use of salivary hormone testing to individualize hormone replacement therapy or to guide sex steroid dosing is not supported. Major societies note methodological limitations — including low hormone concentrations in saliva, potential contamination, circadian and other biologic variability, and lack of standardized reference ranges — which prevent reliable interpretation of salivary sex steroid measurements for dosing decisions.
Testing salivary hormone levels for the purpose of guiding individualized hormone replacement therapy or dosing, including for compounded bio‑identical hormone preparations, is considered not supported and therefore does not meet criteria. Society guidance emphasizes that salivary testing is inaccurate, unreliable, and not standardized for dose titration, and that serum testing — when needed — is preferred.
Procedure Codes and Diagnostic Cut-offs
| 82530 | Cortisol; free. |
| 82533 | Cortisol; total. |
| S3650 | Saliva test, hormone level; during menopause. |
| 0462U | Melatonin levels test, sleep study, 7 or 9 sample melatonin profile (cortisol optional), enzyme-linked immunosorbent assay (ELISA), saliva, screening/preliminary Proprietary Test: Salimetrics® Salivary Melatonin Profile (Circadian Phase Assessment) |
Provider Responsibilities, Authorization, and Testing Recommendations
Authorization and medical necessity
Services must meet authorization and medical necessity guidelines; coverage decisions depend on the member's benefit coverage at the time of the request and applicable state/federal regulations.
LNSC as first-line biochemical test for suspected Cushing syndrome
For individuals with signs and symptoms of Cushing syndrome, late-night salivary cortisol (LNSC) is described as a first-line diagnostic test and meets criteria when used for this indication.
- LNSC identified as a first-line diagnostic test for Cushing syndrome
Recommended testing approach for Cushing's syndrome
The Endocrine Society recommends obtaining at least two late-night salivary cortisol (LNSC) measurements for diagnosis of Cushing syndrome; diagnosis is established when at least two different first-line tests are abnormal.
- Obtain LNSC measurements at least twice
- Diagnosis typically requires two abnormal first-line tests (e.g., LNSC and 24‑hour urinary free cortisol)
Provider responsibility for accurate documentation and coding
Providers are responsible for submission of accurate documentation of services performed and appropriate coding according to industry-standard coding guidelines; failure to do so may result in denial or recoupment.
- Code claims according to CPT, HCPCS, ICD-10, UB, and CMS guidelines as applicable
Documentation for LDT salivary assays
If ordering laboratory-developed salivary assays, document that the assay is regulated under CLIA as a high-complexity LDT and include the clinical rationale, test name, and methodology (when available).
- Document LDT status (CLIA high-complexity)
- Include clinical rationale and test methodology (e.g., ELISA, LC‑MS/MS) and test name when available
Denial risk for noncompliance with coding/billing or coverage rules
Claims may be denied or recouped if coding/billing guidelines or current reimbursement policies are not followed, or if services do not meet authorization and medical necessity guidelines.
- Follow payer-specific reimbursement and coding policies to avoid denials or recoupment
Unsupported use for individualized hormone dosing
Use of salivary hormone testing to guide individualized hormone therapy or determine dosing is unsupported by professional societies and may trigger denial or non-coverage when billed for that purpose.
- Professional guidelines (ACOG/ASRM, Endocrine Society) state salivary testing is not accurate or precise for individualizing therapy
Background and Scope
Salivary testing has been proposed as a noninvasive method to measure the free (unbound) fraction of steroid hormones (e.g., cortisol, estrogens, progesterone, androgens). Proponents suggest saliva reflects unconjugated hormone concentrations and could be used for diagnosis or monitoring. However, the evidence shows variable analytical validity across hormones: cortisol (particularly late‑night salivary cortisol) has supporting data for screening of hypercortisolism, while salivary sex steroid measurements demonstrate poor correlation with serum, large within‑patient variability, and methodological challenges (low concentrations, contamination, and diurnal effects) that limit clinical utility.
Definitions and Abbreviations
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.